Health Law Daily Wrap Up, GENERAL HEALTH CARE NEWS: HHS report prompts OIG review of insurance coding tied to pediatric gender-affirming medical interventions, (Aug 18, 2026)

By Patricia K. Ruiz, J.D.

HHS cited claims data, coding patterns, and existing investigations in its referral for further scrutiny.

HHS has released a report examining insurance coding practices, financial incentives and the provision of gender-affirming medical interventions for minors and has referred identified hospitals and clinics to the Office of Inspector General (OIG) for possible investigation. The report analyzes nationwide claims data, discusses federal healthcare fraud statutes and reviews coding practices associated with puberty blockers and cross-sex hormones. HHS officials said the findings warrant additional review of billing and coding practices and stronger oversight of claims submitted to public health programs.

Report findings. The report examines insurance coding practices, financial incentives, and pediatric gender-affirming medical interventions. According to HHS, the report draws on CMS guidance, Department of Justice (DOJ) investigations, insurance claims analyses, hospital records, whistleblower testimony and interviews with patients and parents. The report states that more than 225 hospitals and health systems established pediatric gender programs nationwide. It also cites an analysis of nationwide claims data from 2015 through 2025 that identified approximately $50 million in insurance claims for puberty blockers billed using diagnostic code E34.9, "Endocrine Disorder, Unspecified," and nearly $11 million in claims involving patients ages 13 to 17 billed with diagnostic code E30.1 for precocious puberty. The report characterizes the findings as signals warranting further review and verification against underlying records.

Billing and coding. The report frames its findings largely through the lens of healthcare fraud and billing compliance. It cites CMS coding standards, federal fraud statutes and recent government healthcare fraud investigations, and contends that inaccurate coding practices could expose providers to civil or criminal liability if proven. At the same time, the report repeatedly states that its claims analysis identifies signals and patterns rather than adjudicated violations and calls for further investigation of the underlying records by appropriate enforcement authorities.

A central focus of the report is whether diagnostic codes used by providers accurately reflected patients' conditions when seeking reimbursement for puberty blockers, hormones or related services. The report discusses federal coding requirements, including CMS guidance directing providers to code documented conditions accurately and with the highest available level of specificity.

The report notes that healthcare fraud statutes may apply when inaccurate diagnostic information is used to obtain payments from public programs or private insurers. It discusses the federal False Claims Act and the federal healthcare fraud statute, citing prior government enforcement actions involving diagnosis coding practices in other healthcare contexts.

HHS' claims analysis identified four categories of billing activity for additional scrutiny, including claims involving puberty blockers billed with endocrine disorder diagnoses, claims involving puberty blockers billed with precocious puberty diagnoses in older adolescents, and certain claims involving cross-sex hormone prescriptions for minors in states with restrictions on such treatments. The report emphasizes that its claims analysis identifies "directional signals" and that findings require verification through review of underlying records.

Recommendations. The report recommends that federal and state agencies review coding and billing practices, strengthen oversight of claims submitted to public healthcare programs and refer billing activity warranting further review for investigation when appropriate. It also recommends periodic reviews of claims associated with diagnosis codes discussed in the report and emphasizes the role of Medicaid program integrity and fraud enforcement mechanisms.

Referral to HHS OIG. HHS Secretary Robert F. Kennedy Jr. sent a referral letter to HHS Inspector General T. March Bell requesting evaluation of hospitals and clinics identified by the report. The letter states that HHS identified "an objectively defined cohort of claims that exhibit potentially anomalous billing patterns" and said those claims justify additional scrutiny by the OIG.

The referral lists organizations associated with four cohorts analyzed in the report, including providers connected to claims involving puberty blockers billed with endocrine disorder diagnoses, precocious puberty diagnoses and certain cross-sex hormone prescriptions. HHS requested that the OIG "swiftly evaluate" the referral in light of the potential violations described in the report.

The HHS press release also states that Vice President JD Vance, in his capacity as chairman of the White House Task Force to Eliminate Fraud, and Secretary Kennedy referred organizations identified in the report to the DOJ and OIG, respectively, for possible violations of federal law.

MainStory: TopStory NewsStory GeneralNews GCNNews BillingNews EnforcementNews ReproductiveHealthCareNews